South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, 3T Biosciences is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Founder, Luke Lee played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About 3T Biosciences
3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach. 3T Biosciences 3T-TRACE platform technology is designed to overcome the challenges of advancing T-cell receptor (TCR)-based therapeutics. Based in South San Francisco, 3T Biosciences is led by an experienced management team and supported by top investors including Westlake Village BioPartners, Lightspeed Venture Partners, and the Parker Institute for Cancer Immunotherapy.

To learn more about 3T Biosciences, visit http://www.3tbiosciences.com/

Contact:
Luke Lee, Founder
650-666-6791
luke.lee@3tbiosciences.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved